A capsule device and a method for the capsule device remain in a very low power state and monitor whether it enters a desired section of the gastrointestinal track. The capsule device is coated with an enteric material that is expected to dissolve after it enters the small bowel. In the monitoring state, the capsule device captures a first image using the camera and the light source at a first frame rate substantially below a target frame rate. The capsule device compares first information related to the first image with second information related to a coating image corresponding to the coating. If the first information does not matches the second information, the capsule device declares that the coating has dissolved and the capsule device configures the camera to capture third images at the target rate after declaring that the coating has dissolved.

The present invention relates to salts of arachidyl amido cholanoic acid (Aramchol), pharmaceutical compositions comprising Aramchol salts, methods for their preparation, and methods of use thereof in medical treatment.

Esterified cellulose ethers which have i) as ester groups aliphatic monovalent acyl groups or groups of the formula —C(O)—R—COOA or a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, and ii) a content of not more than 0.85 weight percent acetone-insoluble esterified cellulose ether particles, when the esterified cellulose ether is present in a mixture of 12.5 weight parts of esterified cellulose ether and 87.5 weight parts of acetone at 21° C., the weight percent acetone-insoluble esterified cellulose ether particles being based on the total weight of the esterified cellulose ether, wherein iii) not more than 14 percent of the acetone-insoluble esterified cellulose ether particles have a particle size of more than 90 micrometers.

A package for delivering a single-dose product includes a softgel capsule which is comprised of at least one gelling agent selected from protein-based gelling agents and polysaccharide-based gelling agents. The capsule shell includes one or more areas of reduced thickness that are preferentially ruptured by exertion of a compressive force on the softgel capsule to create an opening in the capsule shell through which the fill composition can be delivered by spraying or squeezing. A method for manufacturing the softgel capsule having one or more areas of reduced shell thickness is also described.

Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

An anti-infective composition for inhalation, containing, at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof; and an effective amount of a biofilm modifier which is a macrolide compound or salt thereof.

The invention relates to an agent supporting the immunomodularity for the treatment of autoimmune diseases, said agent containing C.sub.3-C.sub.8 carboxylic acids, their physiologically tolerable salts and/or esters with C.sub.1-C.sub.8 alkyl alcohols, their use as supporting immunomodulators for autoimmune related diseases and immune-mediated chronic inflammatory diseases, as well as dietary supplements with immunomodulating effect containing these.

A food for improving intestinal environment by promoting proliferation of intestinal bifidobacteria is described herein. The food for improving intestinal environment can contain a combination of (1) an enteric composition containing an amino acid or a salt thereof and (2) an indigestible polysaccharide or a composition containing an indigestible polysaccharide.

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.